X-Chem acquires IntelliSyn and AviSyn to boost drug discovery service

X-Chem, provider of DNA-Encoded Library (DEL)-based discovery services, has acquired IntelliSyn, a Montreal-based drug discovery services company and its US-based sister company, AviSyn. The transaction will enable the company to offer a complete, seamless solution for screening, hit validation and lead optimisation on existing and new markets. Financial details of the deal have not been disclosed.

Leveraging a proprietary DEX platform with libraries containing over 200 billion small molecules, X-Chem discovers new drug leads for biopharma clients. IntelliSyn’s services will complement X-Chem’s service offering as an additional downstream part of the drug discovery process, primarily in the field of medicinal chemistry, custom synthesis and scale-up process chemistry, supporting lead optimisation through candidate identification.

“The acquisition of IntelliSyn and AviSyn will allow us to significantly extend our capabilities to support drug discovery. This will result in a more streamlined offering to our clients. Fast drug discovery is essential in today’s biopharma industry and our new integrated offering will support our clients by accelerating this phase of their drug discovery journey,” said Matt Clark, Chief Executive Officer at X-Chem.

IntelliSyn’s Founder and CEO Jeffrey Albert will join the X-Chem management team.

“We are excited to join X-Chem and make real impact on our partners’ drug discovery efforts. IntelliSyn and X-Chem share a common dedication to innovation, quality, and scientific excellence. Together we will create a differentiated approach to drug discovery,” said Jeffrey Albert, Founder and CEO at IntelliSyn.

X-Chem’s proprietary DEL technology allows customers to screen billions of compounds simultaneously against a single biological target; faster than conventional high-throughput screening (HTS) methods. The company has licensed over 70 research programs, comprising hundreds of novel chemical entities, to companies throughout the US, Europe, and Japan.

Image credit: National Cancer Institute

 

 

Suggested Reading

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free